retatrutide type 2 diabetes trial results Weight loss with as compared to currently licenced obesity retatrutide weight loss phase 2

Think of it as a messenger that tells your body how to handle the food you just put in it

Tirzepatide (Mounjaro/Zepbound) is a dual GLP-1/GIP agonist that produces weight loss results between semaglutide and retatrutide, with approximately 20-22% average weight loss at the 15 mg dose

Bill insurance for consultations (medical E/M visits for obesity with comorbidities), but: This captures insurance visit fees while avoiding the medication prior-auth death spiral

Injecting in the morning means that peak drug activity, and therefore peak GI effects, occurs during the daytime when you are active and can manage symptoms more easily